Cizzle Biotechnology, a UK-based diagnostics developer of early cancer tests, has raised up to £250,000 through the issue of further unsecured convertible loan notes to Frazer Lang, an existing investor in the company.

In May Cizzle secured funding of £150,000 from Lang to roll out its CIZ1B biomarker test to help detect lung cancer early.

The company has now announced that it has entered into a Letter of Intent with a leading medical diagnostic services provider, acting in partnership with the NHS, as result of that initiative.